key: cord-0939181-xatzttiu authors: Camou, Fabrice; Tinevez, Claire; Beguet‐Yachine, Mathilde; Bellecave, Pantxika; Ratiarison, Diana; Tumiotto, Camille; Lafarge, Xavier; Guisset, Olivier; Mourissoux, Gaëlle; Lafon, Marie‐Edith; Bonnet, Fabrice; Issa, Nahéma title: Feasibility of convalescent plasma therapy in severe COVID‐19 patients with persistent SARS‐CoV‐2 viremia date: 2021-05-03 journal: J Med Virol DOI: 10.1002/jmv.27032 sha: a514fb5de98df3e3a784f5159a72bc1d3c93d299 doc_id: 939181 cord_uid: xatzttiu This study aims to assess the efficacy and safety of convalescent plasma therapy (CPT) in COVID‐19 critically ill patients with protracted severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) RNAemia. A retrospective cohort study was conducted in intensive care unit (ICU). All patients with severe COVID‐19 pneumonia for whom RNAemia remained positive more than 14 days after onset of the infection were included and given CPT. The primary objective was to evaluate SARS‐CoV‐2 RNAemia 7 days (D7) after CPT. A total of 14 patients were included and they received a median CPT volume of 828 ml (range: 817–960). CPT was administered in a median time of 14 days after ICU admission. At D7, 13/14 patients had negative SARS‐CoV‐2 blood PCR and one patient had negative blood PCR 11 days after CPT. At D7 and at D14, the clinical status was improved in 7/14 and 11/14 patients, respectively. The 28‐day mortality rate was 14%. No CPT‐related adverse effects had been reported. CPT is safe and may be efficient in patients with protracted RNAemia admitted in ICU for severe COVID‐19 pneumonia. Randomized controlled trials are needed to confirm these results. The first report of CPT efficacy was reported in an uncontrolled case series in five critically ill patients from China. 8 SARS-CoV-2 viral load appeared to peak in the upper respiratory tract within the first week after symptom onset. 15 Numerous studies identified an association between older age (>60 years) and prolonged viral RNA shedding. Male sex and corticosteroids therapy seem to be two other factors associated with delayed viral clearance. 15 Faster clearance was frequently observed in asymptomatic individuals. Median duration of shedding in serum samples varies from 16.6 days (3.6-29.7) to 21 days (9-39) with a maximum of RNA shedding of 60 days. 15, 16 The clinical significance of SARS-CoV-2 RNA in blood circulation is unknown. It could be associated with free viral particles or altered RNA. Less than 15% of symptomatic COVID-19 patients have RNAemia and no correlation between upper respiratory Ct values and RNAemia frequency or plasma RNA loads, as evaluated by Ct comparison, could be established. 17 Moreover, a very small fraction of blood donors, even those who remain asymptomatic after donation, can be RNAemic for SARS-CoV-2 with low viral loads, as suggested by high Ct, and infectivity of positive plasma was not evidenced in cell culture experiments. [18] [19] [20] Literature data cannot determine yet whether RNAemia represents direct viral involvement in causing extrapulmonary pathology or is merely spill-over from an intense pulmonary infection. 17 However, numerous concordant studies showed that RNAemia is a strong indicator for clinical severity, mainly ARDS, and is detected more frequently in critical patients who were admitted to the ICU and/or died. 11, 17, [20] [21] [22] The individuals with RNAemia were older than those with undetectable SARS-CoV-2 RNA in plasma. 20 In a recent study, Hagman et al. 9 showed that SARS-CoV-2 RNA in serum at admission was associated with a sevenfold increased risk of critical disease and an eightfold increased risk of death in a cohort of 167 patients hospitalized for COVID-19. These apparently conflicting results probably reflect the very variable severity of SARS-CoV-2 infection. In the present study, eligible patients remained symptomatic with persistent viremia, whatever the serological results. Consequently, we hypothesize that these disappointing results obtained by controlled studies could be partially linked to the inclusion criteria and suggest that the viral load or the host's humoral response should be taken into account to define patients who could benefit from CPT in symptomatic/severe COVID-19 pneumonia, especially in older patients. These results underline the key role of neutralizing humoral immunity. Nevertheless, our study confirms that some patients failed to clear the virus despite apparent humoral response. In these patients, as other authors have already reported, IgG and IgM titers were much higher than they were in less symptomatic individuals. 23, 24 At first glance, the efficacy of CPT is of course more difficult to Our study suggests that passive transfer of SARS-CoV-2-neutralizing antibodies through CPT is safe and may be efficient in severe COVID-19 patients with protracted RNAemia beyond 14 days despite positive serology, especially in older patients. RCTs are needed to confirm this therapeutic option in viremic critically ill patients. The authors declare that there are no conflict of interests. Fabrice Bonnet: participated in study enrollment. All authors critically revised and approved the manuscript. The data that support the findings of this study are available from the corresponding author upon reasonable request. ORCID Nahéma Issa http://orcid.org/0000-0002-3443-6115 Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19 Convalescent plasma transfusion for the treatment of COVID-19: Systematic review Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and lifethreatening COVID-19: a randomized clinical trial A randomized trial of convalescent plasma in Covid-19 severe pneumonia Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomized, controlled, open-label, platform trial. medRxiv Décision du 29/04/2020 autorisant la collecte, la préparation, la conservation, la distribution et la délivrance du produit sanguin labile « plasma convalescent Covid-19 Severe COVID-19 in patients with B cell alymphocytosis and response to convalescent plasma therapy Treatment of 5 critically ill patients with COVID-19 with convalescent plasma Severe acute respiratory syndrome coronavirus 2 RNA in serum as predictor of severe outcome in coronavirus disease 2019: a retrospective cohort study Effectiveness of convalescent plasma therapy in severe COVID-19 patients Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization Use of convalescent plasma in hospitalized patients with COVID-19: case series Treatment of coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality Early high-titer plasma therapy to prevent severe Covid-19 in older adults SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and metaanalysis Dynamics of blood viral load is strongly associated with clinical outcomes in coronavirus disease 2019 (COVID-19) patients: a prospective cohort study Severe acute respiratory syndrome coronavirus 2 RNA in plasma is associated with intensive care unit admission and mortality in patients hospitalized with coronavirus disease 2019 Severe acute respiratory syndrome coronavirus 2 RNA detected in blood donations No evidence of SARS-CoV-2 transfusion transmission despite RNA detection in blood donors showing symptoms after donation High frequency of SARS-CoV-2 RNAemia and association with severe disease Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019 SARS-CoV-2 viral load is associated with increased disease severity and mortality SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates RNAemia corresponds to disease severity and antibody response in hospitalized COVID-19 patients Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks